JP2008508885A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508885A5
JP2008508885A5 JP2007525033A JP2007525033A JP2008508885A5 JP 2008508885 A5 JP2008508885 A5 JP 2008508885A5 JP 2007525033 A JP2007525033 A JP 2007525033A JP 2007525033 A JP2007525033 A JP 2007525033A JP 2008508885 A5 JP2008508885 A5 JP 2008508885A5
Authority
JP
Japan
Prior art keywords
antibody
use according
group
antigen
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007525033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/027912 external-priority patent/WO2006135385A2/en
Publication of JP2008508885A publication Critical patent/JP2008508885A/ja
Publication of JP2008508885A5 publication Critical patent/JP2008508885A5/ja
Withdrawn legal-status Critical Current

Links

JP2007525033A 2004-08-05 2005-08-05 インターロイキン−21受容体活性を中和すること Withdrawn JP2008508885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59908604P 2004-08-05 2004-08-05
US63917604P 2004-12-23 2004-12-23
PCT/US2005/027912 WO2006135385A2 (en) 2004-08-05 2005-08-05 Antagonizing interleukin-21 receptor activity

Publications (2)

Publication Number Publication Date
JP2008508885A JP2008508885A (ja) 2008-03-27
JP2008508885A5 true JP2008508885A5 (enExample) 2008-09-04

Family

ID=37309615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007525033A Withdrawn JP2008508885A (ja) 2004-08-05 2005-08-05 インターロイキン−21受容体活性を中和すること

Country Status (16)

Country Link
US (2) US20060039902A1 (enExample)
EP (1) EP1773394A2 (enExample)
JP (1) JP2008508885A (enExample)
KR (1) KR20070057789A (enExample)
AR (1) AR051071A1 (enExample)
AU (1) AU2005332996A1 (enExample)
BR (1) BRPI0514138A (enExample)
CA (1) CA2574848A1 (enExample)
CR (1) CR8891A (enExample)
EC (1) ECSP077226A (enExample)
IL (1) IL181044A0 (enExample)
MX (1) MX2007001509A (enExample)
NO (1) NO20070973L (enExample)
RU (1) RU2007102287A (enExample)
TW (1) TW200608995A (enExample)
WO (1) WO2006135385A2 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
US20110075507A1 (en) * 1997-10-24 2011-03-31 Revalesio Corporation Diffuser/emulsifier
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
MXPA05000655A (es) * 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
MXPA05009556A (es) 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
RU2005132458A (ru) * 2003-03-21 2006-03-20 Уайт (Us) Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21
WO2006088925A2 (en) 2005-02-14 2006-08-24 Wyeth Use of il17-f in diagnosis and therapy of airway inflammation
CN101218254A (zh) * 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
AU2006237329B2 (en) 2005-04-18 2012-04-12 Novo Nordisk A/S IL-21 variants
US8470316B2 (en) * 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
RU2450830C2 (ru) * 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) * 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
EP1960433A2 (en) * 2005-11-28 2008-08-27 Zymogenetics, Inc. Il-21 receptor antagonists
JP5033643B2 (ja) * 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
JP5754875B2 (ja) * 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
US8784898B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of wound care and treatment
US8784897B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of therapeutic treatment of eyes
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
WO2008115290A2 (en) * 2006-10-25 2008-09-25 Revalesio Corporation Methods of wound care and treatment
US8609148B2 (en) * 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
AU2007308840C1 (en) 2006-10-25 2014-09-25 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
EP2086668B1 (en) 2006-10-25 2016-11-16 Revalesio Corporation Mixing device and method
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
EP2109620B1 (en) * 2006-12-21 2012-08-22 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
MX2009007830A (es) * 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US10125359B2 (en) * 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US20100015235A1 (en) * 2008-04-28 2010-01-21 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20100303918A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
AU2008316708A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20100303871A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100303917A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating cystic fibrosis
US20090263495A1 (en) * 2007-10-25 2009-10-22 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20100009008A1 (en) * 2007-10-25 2010-01-14 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20100029764A1 (en) * 2007-10-25 2010-02-04 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US9745567B2 (en) * 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
WO2010062628A1 (en) * 2008-10-27 2010-06-03 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
EP2217268B1 (en) 2007-12-07 2016-05-04 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
JP2011512877A (ja) * 2008-03-12 2011-04-28 ワイス・エルエルシー 組換えタンパク質の大スケール産生に適した細胞を同定する方法
WO2009132821A1 (en) * 2008-04-28 2009-11-05 Giuliani International Limited Interleukin (il-21) binding proteins and methods of making and using same
EP2285347A4 (en) * 2008-05-01 2011-09-21 Revalesio Corp COMPOSITIONS AND METHODS OF TREATING DISORDERS OF THE DIGESTION SYSTEM
AR071885A1 (es) 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21
CN102149403A (zh) * 2008-05-23 2011-08-10 惠氏有限责任公司 利用白介素-21受体结合蛋白的治疗方法
TW201503898A (zh) * 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
WO2010039533A2 (en) 2008-09-23 2010-04-08 Wyeth Methods for predicting production of activating signals by cross-linked binding proteins
ES2632213T3 (es) * 2008-10-08 2017-09-11 Cambridge Enterprise Limited Métodos y composiciones para diagnosticar y tratar una enfermedad autoinmunitaria que es secundaria con respecto a la esclerosis múltiple
US20100098659A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
EP2467160B1 (en) * 2009-08-17 2016-11-16 A & G Pharmaceutical, Inc. Materials and methods for the development of an antigen-specific immune non-responsiveness state
KR101004363B1 (ko) * 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 자가 면역 질환 예방 및 치료용 TNF-α와 IL-21 이중 길항제
WO2011119404A1 (en) * 2010-03-26 2011-09-29 Monsanto Technology Llc Portable systems and methods for amplifying nucleotides and detecting nucleotide sequences
NZ604063A (en) 2010-05-07 2015-01-30 Revalesio Corp Compositions and methods for enhancing physiological performance and recovery time
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
US20130224109A1 (en) * 2010-07-20 2013-08-29 Beth Israel Deaconess Medical Center, Inc. Compositions and methods featuring il-6 and il-21 antagonists
AU2011289172B2 (en) 2010-08-12 2015-09-24 Revalesio Corporation Compositions and methods for treatment of taupathy
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
KR20130011056A (ko) * 2011-07-20 2013-01-30 주식회사에이앤알쎄라퓨틱스 염증표적 수용체 및 염증 질환 치료용 약물 운반체
EP2565881B1 (en) * 2011-08-30 2018-06-13 ABB Schweiz AG Dry-type transformer
WO2013096732A2 (en) * 2011-12-23 2013-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing viral diseases by blocking interleukin-21
WO2014172606A1 (en) * 2013-04-19 2014-10-23 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
AU2015244025B2 (en) 2014-04-08 2019-03-21 Boston Pharmaceuticals Inc. Binding molecules specific for IL-21 and uses thereof
CN107249633A (zh) * 2014-12-19 2017-10-13 迈博太科公司 用于抑制il‑21介导的人细胞活化的组合物、试剂盒和方法
EP3978512A1 (en) 2015-10-09 2022-04-06 Bioniz, LLC Modulating gamma-c-cytokine activity
KR102908806B1 (ko) 2015-10-22 2026-01-07 주노 테라퓨틱스 게엠베하 세포의 배양 방법 및 이를 위한 키트와 장치
WO2018013585A1 (en) * 2016-07-12 2018-01-18 Flagship Pioneering, Inc. Methods and compositions for modulating thymic function
WO2018038898A2 (en) * 2016-08-05 2018-03-01 The Regents Of The University Of California Mithrene and methods of fabrication of mithrene
KR102707650B1 (ko) 2017-04-07 2024-09-19 바이오니즈 테라퓨틱스, 아이엔씨. 감마-c-사이토카인 활성의 안정한 조절자
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
CN110124029B (zh) * 2019-04-19 2023-08-11 中山大学附属第六医院 Il-6r抗体及羊水干细胞在制备用于治疗nec的药物中的应用
BR112021021878A2 (pt) 2019-05-03 2022-01-18 Bioniz Llc Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados
WO2022093683A1 (en) * 2020-10-26 2022-05-05 Neptune Biosciences Llc Orthogonal il-21 receptor/cytokine systems
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
CN119020389A (zh) * 2024-08-26 2024-11-26 江苏省人民医院(南京医科大学第一附属医院) 一种具备il-6r纳米抗体分泌功能的重组枯草芽孢杆菌及其构建方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US425871A (en) * 1890-04-15 Half to james l
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US6350892B1 (en) * 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
ES2279809T3 (es) * 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
EP3254687A1 (en) * 2001-10-04 2017-12-13 Genetics Institute LLC Methods and compositions for modulating interleukin-21 receptor activity
AU2003230834A1 (en) * 2002-04-09 2003-10-27 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
MXPA05000655A (es) * 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
RU2005132458A (ru) * 2003-03-21 2006-03-20 Уайт (Us) Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21
EP1753458A4 (en) * 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis

Similar Documents

Publication Publication Date Title
RU2007102287A (ru) Антагонисты активности рецептора интерлейкина-21
CN102307896B (zh) 基于iii型纤连蛋白结构域的支架组合物、方法及用途
JP2021520374A (ja) 移植可能な粒子及び関連方法
JP2021507690A5 (enExample)
JP2020534837A (ja) 活性細胞を含む方法、組成物、及び移植可能な要素
WO2010055366A4 (en) Anti-human il-21 monoclonal antibodies
JP2004248677A5 (enExample)
CN106188297B (zh) 抗CTLA-4的纳米抗体Nb91及其制备方法与应用
JP2016518823A5 (enExample)
JP2012507994A (ja) Hla−gタンパク質及びその薬学的使用
JP2015504675A5 (enExample)
WO2022166831A1 (zh) 吸附细胞因子的重组融合蛋白、纳米组装体及其制备方法与应用
EP1299522B1 (en) Alteration of cell membrane
CN115028719B (zh) 血清白蛋白结合纳米抗体及其制备方法与应用
CN109897107A (zh) 纳米抗体及其制备方法
CN117866904A (zh) 基于单域抗体基因修饰的干细胞对于多种的疾病的制药用途
CN117384286B (zh) 针对gpa33的单域抗体及其衍生蛋白和应用
CN120518751B (zh) 抗人4型腺病毒特异性纳米抗体lum44及在抗病毒治疗中的应用
CN112805302B (zh) 抗BCMA单链抗体scFv及其制备方法和应用
CN117860786B (zh) 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途
CN118184786B (zh) 一种靶向gpc3的鲨鱼单域抗体vnar-f10及其应用
CN104725514A (zh) 新型il23拮抗剂
CN118001428A (zh) 基因修饰干细胞在il-17靶点相关疾病中的应用
JP2025521755A (ja) 共有結合架橋多糖及びその使用方法
CN102241776A (zh) Rankl-tnf样区融合蛋白及其制备方法和应用